Oxytocin as an Anti-obesity Treatment
Obesity is a growing health concern, as it increases risk for heart disease, hypertension, type 2 diabetes, cancer, COVID-19 related hospitalizations and mortality. However, current weight loss therapies are often associated with psychiatric or cardiovascular side effects or poor tolerability that l...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2021.743546/full |
| _version_ | 1831769115379892224 |
|---|---|
| author | JingJing Niu JingJing Niu Jenny Tong Jenny Tong James E. Blevins James E. Blevins |
| author_facet | JingJing Niu JingJing Niu Jenny Tong Jenny Tong James E. Blevins James E. Blevins |
| author_sort | JingJing Niu |
| collection | DOAJ |
| description | Obesity is a growing health concern, as it increases risk for heart disease, hypertension, type 2 diabetes, cancer, COVID-19 related hospitalizations and mortality. However, current weight loss therapies are often associated with psychiatric or cardiovascular side effects or poor tolerability that limit their long-term use. The hypothalamic neuropeptide, oxytocin (OT), mediates a wide range of physiologic actions, which include reproductive behavior, formation of prosocial behaviors and control of body weight. We and others have shown that OT circumvents leptin resistance and elicits weight loss in diet-induced obese rodents and non-human primates by reducing both food intake and increasing energy expenditure (EE). Chronic intranasal OT also elicits promising effects on weight loss in obese humans. This review evaluates the potential use of OT as a therapeutic strategy to treat obesity in rodents, non-human primates, and humans, and identifies potential mechanisms that mediate this effect. |
| first_indexed | 2024-12-22T07:15:03Z |
| format | Article |
| id | doaj.art-3da81f8124b0432a8bb0899d3c26f48a |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-12-22T07:15:03Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-3da81f8124b0432a8bb0899d3c26f48a2022-12-21T18:34:25ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2021-10-011510.3389/fnins.2021.743546743546Oxytocin as an Anti-obesity TreatmentJingJing Niu0JingJing Niu1Jenny Tong2Jenny Tong3James E. Blevins4James E. Blevins5VA Puget Sound Health Care System, Office of Research and Development, Medical Research Service, Department of Veterans Affairs Puget Sound Health Care System, Seattle, WA, United StatesDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United StatesVA Puget Sound Health Care System, Office of Research and Development, Medical Research Service, Department of Veterans Affairs Puget Sound Health Care System, Seattle, WA, United StatesDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United StatesVA Puget Sound Health Care System, Office of Research and Development, Medical Research Service, Department of Veterans Affairs Puget Sound Health Care System, Seattle, WA, United StatesDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United StatesObesity is a growing health concern, as it increases risk for heart disease, hypertension, type 2 diabetes, cancer, COVID-19 related hospitalizations and mortality. However, current weight loss therapies are often associated with psychiatric or cardiovascular side effects or poor tolerability that limit their long-term use. The hypothalamic neuropeptide, oxytocin (OT), mediates a wide range of physiologic actions, which include reproductive behavior, formation of prosocial behaviors and control of body weight. We and others have shown that OT circumvents leptin resistance and elicits weight loss in diet-induced obese rodents and non-human primates by reducing both food intake and increasing energy expenditure (EE). Chronic intranasal OT also elicits promising effects on weight loss in obese humans. This review evaluates the potential use of OT as a therapeutic strategy to treat obesity in rodents, non-human primates, and humans, and identifies potential mechanisms that mediate this effect.https://www.frontiersin.org/articles/10.3389/fnins.2021.743546/fullobesityfood intakeenergy expenditureoxytocin - therapeutic useadipose tissue |
| spellingShingle | JingJing Niu JingJing Niu Jenny Tong Jenny Tong James E. Blevins James E. Blevins Oxytocin as an Anti-obesity Treatment Frontiers in Neuroscience obesity food intake energy expenditure oxytocin - therapeutic use adipose tissue |
| title | Oxytocin as an Anti-obesity Treatment |
| title_full | Oxytocin as an Anti-obesity Treatment |
| title_fullStr | Oxytocin as an Anti-obesity Treatment |
| title_full_unstemmed | Oxytocin as an Anti-obesity Treatment |
| title_short | Oxytocin as an Anti-obesity Treatment |
| title_sort | oxytocin as an anti obesity treatment |
| topic | obesity food intake energy expenditure oxytocin - therapeutic use adipose tissue |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2021.743546/full |
| work_keys_str_mv | AT jingjingniu oxytocinasanantiobesitytreatment AT jingjingniu oxytocinasanantiobesitytreatment AT jennytong oxytocinasanantiobesitytreatment AT jennytong oxytocinasanantiobesitytreatment AT jameseblevins oxytocinasanantiobesitytreatment AT jameseblevins oxytocinasanantiobesitytreatment |